For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer

Clinical Trial Title: 
A phase 1b/2, open-label, dose escalation study of entinostat in combination with pembrolizumab in patients with non-small cell lung cancer, with expansion cohorts in patients with NSCLC, melanoma, and mismatch repair-proficient colorectal cancer.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Philip D. Bonomi, MD
Clinical Trial Protocol Description: 

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Additionally the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with NSCLC, melanoma, and mismatch-repair proficient colorectal cancer.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are 18 years of age or older.
  • Have confirmed recurrent/metastatic NSCLC.
  • Have a confirmed diagnosis of unresectable or metastatic melanoma.
  • Have received at least one chemotherapeutic regimen in the advanced/metastatic setting for colorectal cancer.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Gastrointestinal Cancers
Lung and Chest Tumors
Melanoma and Soft Tissue
Contact Phone: 
(312) 563-3347
Contact Name: 
Deborah Pach, RN